Publications
Detailed Information
Pretreatment of epidermal growth factor promotes primary hair recovery via the dystrophic anagen pathway after chemotherapy-induced alopecia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Paik, Seung Hwan | - |
dc.contributor.author | Yoon, Ji-Seon | - |
dc.contributor.author | Ryu, Hyeong Ho | - |
dc.contributor.author | Lee, Ji Yeon | - |
dc.contributor.author | Shin, Chang Yup | - |
dc.contributor.author | Min, Kyung Hyun | - |
dc.contributor.author | Jo, Seong Jin | - |
dc.contributor.author | Kim, Kyu Han | - |
dc.contributor.author | Kwon, Ohsang | - |
dc.creator | 권오상 | - |
dc.date.accessioned | 2013-09-23T04:31:00Z | - |
dc.date.available | 2013-09-23T04:31:00Z | - |
dc.date.issued | 2013-07 | - |
dc.identifier.citation | Experimental Dermatology Vol.22 No.7, pp. 496-499 | - |
dc.identifier.issn | 0906-6705 (print) | - |
dc.identifier.issn | 1600-0625 (online) | - |
dc.identifier.uri | https://hdl.handle.net/10371/83437 | - |
dc.description.abstract | Epidermal growth factor (EGF) is not only a cell growth stimulant but also has a catagen-inducing effect. Because chemotherapeutic agents primarily damage anagen hair follicles, it would be important to investigate whether catagen inducers have beneficial effects in chemotherapy-induced alopecia (CIA). We pretreated hair follicles with topical EGF-liposomal solution in the C57BL/6 mouse model of cyclophosphamide-induced alopecia and observed the catagen-inducing property and damage response pathway after CIA. We confirmed that topical EGF application induced a catagen-like stage and found that these catagen-like hairs were protected from chemotherapy-mediated damage. Moreover, our results showed that EGF treatment favoured primary hair recovery via the dystrophic anagen pathway after CIA. Given that hair follicles subjected to less severe chemotherapeutic insult enter the dystrophic anagen pathway followed by primary recovery, the results of this study suggest that catagen inducers could be useful as a new alopecia-protection strategy, especially in the context of CIA. | en |
dc.description.sponsorship | This research was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (No: 2012R1A1A2005302). | - |
dc.language.iso | en | en |
dc.publisher | John Wiley & Sons | en |
dc.subject | 의약학 | en |
dc.subject | chemotherapy-induced alopecia | - |
dc.subject | dystrophic anagen pathway | - |
dc.subject | epidermal growth factor | - |
dc.subject | primary hair recovery | - |
dc.title | Pretreatment of epidermal growth factor promotes primary hair recovery via the dystrophic anagen pathway after chemotherapy-induced alopecia | en |
dc.type | Article | - |
dc.author.alternative | 백승환 | - |
dc.author.alternative | 윤지선 | - |
dc.author.alternative | 류형호 | - |
dc.author.alternative | 이지윤 | - |
dc.author.alternative | 신창엽 | - |
dc.author.alternative | 민규현 | - |
dc.author.alternative | 조승진 | - |
dc.author.alternative | 김규한 | - |
dc.author.alternative | 권오상 | - |
dc.identifier.doi | 10.1111/exd.12182 | - |
dc.citation.journaltitle | Experimental Dermatology | - |
dc.description.srnd | OAIID:oai:osos.snu.ac.kr:snu2013-01/102/0000045457/4 | - |
dc.description.srnd | SEQ:4 | - |
dc.description.srnd | PERF_CD:SNU2013-01 | - |
dc.description.srnd | EVAL_ITEM_CD:102 | - |
dc.description.srnd | USER_ID:0000045457 | - |
dc.description.srnd | ADJUST_YN:N | - |
dc.description.srnd | EMP_ID:A079130 | - |
dc.description.srnd | DEPT_CD:801 | - |
dc.description.srnd | CITE_RATE:3.543 | - |
dc.description.srnd | FILENAME:paik sh, et al exp dermatol 2013.pdf | - |
dc.description.srnd | DEPT_NM:의학과 | - |
dc.description.srnd | EMAIL:oskwon@snu.ac.kr | - |
dc.description.srnd | SCOPUS_YN:Y | - |
dc.description.srnd | CONFIRM:Y | - |
dc.identifier.srnd | 2013-01/102/0000045457/4 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.